RU2019131098A3 - - Google Patents

Download PDF

Info

Publication number
RU2019131098A3
RU2019131098A3 RU2019131098A RU2019131098A RU2019131098A3 RU 2019131098 A3 RU2019131098 A3 RU 2019131098A3 RU 2019131098 A RU2019131098 A RU 2019131098A RU 2019131098 A RU2019131098 A RU 2019131098A RU 2019131098 A3 RU2019131098 A3 RU 2019131098A3
Authority
RU
Russia
Application number
RU2019131098A
Other languages
Russian (ru)
Other versions
RU2019131098A (ru
RU2757932C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019131098A publication Critical patent/RU2019131098A/ru
Publication of RU2019131098A3 publication Critical patent/RU2019131098A3/ru
Application granted granted Critical
Publication of RU2757932C2 publication Critical patent/RU2757932C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
RU2019131098A 2017-04-05 2018-03-28 Генетическая конструкция для применения при лечении нейродегенеративного нарушения или инсульта RU2757932C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1705484.2A GB201705484D0 (en) 2017-04-05 2017-04-05 Genetic construct
GB1705484.2 2017-04-05
PCT/GB2018/050824 WO2018185468A1 (en) 2017-04-05 2018-03-28 Genetic construct for use in the treatment of neurodegenerative disorder or stroke

Publications (3)

Publication Number Publication Date
RU2019131098A RU2019131098A (ru) 2021-05-05
RU2019131098A3 true RU2019131098A3 (cg-RX-API-DMAC7.html) 2021-07-27
RU2757932C2 RU2757932C2 (ru) 2021-10-25

Family

ID=58682577

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019131098A RU2757932C2 (ru) 2017-04-05 2018-03-28 Генетическая конструкция для применения при лечении нейродегенеративного нарушения или инсульта

Country Status (14)

Country Link
US (1) US20200046850A1 (cg-RX-API-DMAC7.html)
EP (1) EP3606546B1 (cg-RX-API-DMAC7.html)
JP (1) JP7296321B2 (cg-RX-API-DMAC7.html)
KR (1) KR102616629B1 (cg-RX-API-DMAC7.html)
CN (1) CN110809476B (cg-RX-API-DMAC7.html)
AU (1) AU2018248651B2 (cg-RX-API-DMAC7.html)
CA (1) CA3058549A1 (cg-RX-API-DMAC7.html)
ES (1) ES2881176T3 (cg-RX-API-DMAC7.html)
GB (1) GB201705484D0 (cg-RX-API-DMAC7.html)
MX (1) MX2019012000A (cg-RX-API-DMAC7.html)
PL (1) PL3606546T3 (cg-RX-API-DMAC7.html)
PT (1) PT3606546T (cg-RX-API-DMAC7.html)
RU (1) RU2757932C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018185468A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200057051A (ko) * 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
JP2022514863A (ja) * 2018-12-19 2022-02-16 ヴェルサメブ アーゲー タンパク質をコードするrna
WO2020179844A1 (ja) 2019-03-04 2020-09-10 公益財団法人東京都医学総合研究所 Trk断片をコードする核酸構築物、及びその利用
US12649930B2 (en) 2019-03-27 2026-06-09 Sigilon Therapeutics, Inc. Compositions, devices, and methods for treating Fabry disease
GB202004832D0 (en) * 2020-04-01 2020-05-13 Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
EP4262846A4 (en) * 2020-12-18 2024-11-20 Baylor College of Medicine ADMINISTRATION OF ABETA VARIANTS FOR INHIBITION OF AGGREGATION
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用
CN118256562A (zh) * 2022-12-26 2024-06-28 科辉智药(深圳)新药研究中心有限公司 一种用于中枢神经系统疾病治疗的基因序列构建体及其应用
KR20250142340A (ko) 2023-02-02 2025-09-30 퀘세라 리미티드 재조합 아데노-부속 바이러스 벡터
EP4413993A1 (en) * 2023-02-10 2024-08-14 Dompe' Farmaceutici S.P.A. Method of obtaining recombinant human brain-derived neurotrophic factor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588221C (en) * 1999-06-08 2013-07-09 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
US9265843B2 (en) 2008-03-27 2016-02-23 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor
EP3165537A1 (en) * 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
ES2694592T3 (es) * 2012-03-15 2018-12-21 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct

Also Published As

Publication number Publication date
JP7296321B2 (ja) 2023-06-22
RU2019131098A (ru) 2021-05-05
US20200046850A1 (en) 2020-02-13
AU2018248651B2 (en) 2024-07-25
MX2019012000A (es) 2020-01-27
RU2757932C2 (ru) 2021-10-25
GB201705484D0 (en) 2017-05-17
CN110809476A (zh) 2020-02-18
JP2020516244A (ja) 2020-06-11
PL3606546T3 (pl) 2021-11-08
KR102616629B1 (ko) 2023-12-21
CA3058549A1 (en) 2018-10-11
EP3606546B1 (en) 2021-04-28
WO2018185468A1 (en) 2018-10-11
KR20200005549A (ko) 2020-01-15
EP3606546A1 (en) 2020-02-12
CN110809476B (zh) 2024-02-27
AU2018248651A1 (en) 2019-10-17
ES2881176T3 (es) 2021-11-29
PT3606546T (pt) 2021-07-12

Similar Documents

Publication Publication Date Title
BR122021000189A2 (cg-RX-API-DMAC7.html)
BR112019008823A2 (cg-RX-API-DMAC7.html)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112019023976B1 (pt) Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde
BR112020003314B1 (pt) Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica
BR112020003112B1 (pt) Método de garantir a viabilidade de uma máquina para uma tarefa agendada
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112020001262B1 (pt) Processo para preparar uma composição de entrega de fármaco
BR112020003569B1 (pt) Método e disposição para transmissão de dados comutados por pacote entre dispositivos de emissão e recepção marítimos para uma embarcação marítima e dispositivos de emissão e recepção terrestres por interfaces aéreas
BR112020000320B1 (pt) Dispositivo bioerodível de administração de fármacos, seu método de preparação, e uso de uma folha não-tecido
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112019027876B1 (pt) Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações
BR112020001354B1 (pt) Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019026880B1 (pt) Método de comunicação, método para receber dados, e, dispositivo
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR102018003507B1 (pt) Sistema de isolamento de tensão de tambor de guincho
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante
BR112019017156B1 (pt) Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador
BR112020006250B1 (pt) Primeira estação base e método de controle de estado em uma primeira estação base
BR112020009459B1 (pt) Método para indicar informações de domínio de frequência do conjunto de recursos de controle comum de informações mínimas remanescentes do sistema